About Enhancer
| Enhancer ID: | E_00326 |
| Species: | Homo sapiens |
| Position : | chr1:3560600-3600000   |
| Year: | 2022 |
| Title: | Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | adult T-cell leukemia/lymphoma |
| PMID: | 35908104 |
| MONDO: | MONDO:0005026 |
| Tissue: | Peripheral Blood |
| Tissue Ontology ID: | UBERON:0000178 |
| Cell Source: | T cell leukemia cell |
| CVCL ID: | |
| Cell Type: | T cell |
| Cell Ontology ID: | CL:0000084 |
| Experiment Type: | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| High Throughput Method: | ChIP-seq, RNA-seq, Hi-ChIP |
| Low Throughput Method: | CRISPR Knockout, CRISPRi, RT-RT-qPCR, Western blot |
About Target Gene
| Target gene : | TP73 |
About TF
| TF name : | IRF4 |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| IRF4 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | pid | 50 |
| IRF4 | IL4-mediated signaling events | pid | 66 |
| IRF4 | Interferon alpha/beta signaling | reactome | 67 |
| IRF4 | Interferon gamma signaling | reactome | 88 |
| IRF4 | Hs_B_Cell_Receptor_Signaling_Pathway_WP23_89900 | wikipathways | 71 |
Enhancer Associated Network
Overlapping Enhancers (hg19)
5 found
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_00327 | chr1:3560600-3600000 | Peripheral Blood | T cell | adult T-cell leukemia/lymphoma |
| E_00328 | chr1:3572730-3574116 | Peripheral Blood | T cell | adult T-cell leukemia/lymphoma |
| E_00329 | chr1:3572730-3574116 | Blood | chronic myeloid leukemia cell | chronic myeloid leukemia |
| E_00330 | chr1:3592595-3594569 | Blood | macrophage | -- |
| E_00331 | chr1:3592595-3594569 | Peripheral Blood | T cell | adult T-cell leukemia/lymphoma |
Expression of Target Genes for the Enhancer